Jasper Hellweg

Q: What is Jasper Hellweg's success rate?

Jasper Hellweg currently has a success rate of 100.

Q: What is the average return of Jasper Hellweg's calls?

Their stock ratings have generated an average return of 2.221577052632687.

Argus Research | Healthcare

Jasper Hellweg is an analyst from Argus Research specializing in the Healthcare sector. They are beginning to establish their track record, with 4 stock ratings so far. Their current stats show a success rate of 100.00% and an average return of 2.22%.

Jasper Hellweg has only issued 4 ratings so far. While the sample size is small, their early calls show a success rate of 100.00% and an average return of 2.22%. Investors may find their initial activity in the Healthcare sector worth watching as they build a track record.

#1841

Out of 4752

Total Ratings

+100.00%

Success Rate

+2.22%

Average Return

Recent Ratings Analysis

BMY

Buy

Aug 05, 2026

Target

$75.00

Current

$64.15

Performance

0.82%

Jasper Hellweg rated BMY as Buy on Aug 05, 2026, setting a price target of 75. Shares have remained stable near 64.15, leaving the 75 target still in play.

AMGN

Buy

Feb 06, 2026

Target

$400.00

Current

$404.85

Performance

5.34%

On Feb 06, 2026, AMGN was given a Buy rating by Jasper Hellweg, with a target price of 400. The stock rallied 5.34% after the rating, narrowing the gap to the target of 400 and validating the bullish stance.

BAX

Hold

Oct 31, 2025

Target

—

Current

$27.01

Performance

46.24%

BAX received a Hold rating from Jasper Hellweg on Oct 31, 2025, aiming for null. Investors saw gains of 46.24% that the cautious stance didn’t fully capture.

ZTS

Buy

Sep 09, 2025

Target

$190.00

Current

$77.23

Performance

-48.44%

On Sep 09, 2025, Jasper Hellweg published a Buy outlook on ZTS, with a target of 190. Market action contradicted the Buy thesis, as shares slipped to 77.23.

BIIB

Hold

Apr 04, 2025

Target

—

Current

$206.28

Performance

67.73%

Jasper Hellweg on Apr 04, 2025 assigned BIIB a Hold rating, with a price target of null. Shares outperformed expectations, climbing 67.73% despite the neutral view.

ILMN

Buy

Aug 28, 2024

Target

$150.00

Current

$193.72

Performance

47.09%

On Aug 28, 2024, Jasper Hellweg reaffirmed ILMN with a Buy rating, targeting 150. The recommendation was supported by strong follow-through as the stock rose from 193.72 to 193.72.

SNY

Buy

Jul 26, 2024

Target

$60.00

Current

$42.89

Performance

-18.15%

SNY was rated Buy by Jasper Hellweg on Jul 26, 2024, with a price objective of 60. This case shows how bullish projections can fail, with the stock now below 42.89.

REGN

Buy

Jun 25, 2024

Target

$1170.00

Current

$772.11

Performance

-27.92%

On Jun 25, 2024, Jasper Hellweg initiated coverage on REGN with a Buy rating and target of 1170. The Buy call has yet to be validated as shares remain 397.89 away from the target.

VRTX

Buy

Jun 17, 2024

Target

$550.00

Current

$484.03

Performance

2.18%

Jasper Hellweg issued a Buy recommendation for VRTX on Jun 17, 2024, price target set at 550. The target of 550 remains in play, though confirmation will depend on future moves.

Frequency Asked Questions

Who is Jasper Hellweg?

Jasper Hellweg is an analyst from Argus Research specializing in the Healthcare sector.

What is Jasper Hellweg's success rate?

Jasper Hellweg currently has a success rate of +100.00%.

How many ratings has Jasper Hellweg issued?

Jasper Hellweg has issued 4 stock ratings so far.

What is the average return of Jasper Hellweg's calls?

Their stock ratings have generated an average return of +2.22%.

What is Jasper Hellweg's ranking?

Jasper Hellweg is ranked #1841 out of 4752 analysts.

What types of ratings does Jasper Hellweg give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Jasper Hellweg?

You can follow Jasper Hellweg by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Jasper Hellweg?

Their latest rating was a Buy on BMY issued on 2026-08-05.